Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compound is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.


Net sales
Gross margin
Net income